Table 2.

Summary of E6 mutant studies

HPV-16 E6 proteinMutant classBindingap53 degradationa at:p53 levels in MECsMEC immortalizationb
E6-APE6BPp5325°C37°CEarly passageLate passage
Wild type+++++++++++++++LowLow6 (6)
H24L/I27Vc I+++++++++++++++LowLow3 (3)
K34Ec I+++++++++++++++LowLow3 (3)
Q35Rc I+++++++++++++++LowLow3 (3)
Y84Cc I+++++++/−++++++LowLow3 (3)
I101Vc I+++++++++++++LowLow3 (3)
E114AI+NDd +++++++LowLow2 (2)
H118DI+/−+/−++++++LowLow1 (1)
H118NI++++++++++++LowLow1 (1)
Δ118-122c I++/−LowLow3 (3)
F125VI+/−+/−+++++LowLow2 (2)
I128TI+/−+/−+/−+++IntermediateLow3 (3)
G134VI+/−+/−++++LowLow2 (2)
L37SII+/−+/−++NormalLow1 (2)
Q107RII+/−+/−+/−++++NormalLow3 (3)
L110QIINormalLow1 (2)
W132Rc II+/−+/−NormalLow1 (4)
F2VIII+++++++/−NormalNormal3 (4)
Y54HIII++++++++++NormalNormal4 (4)
C63R/Y70C/K72R/T86Sc NormalNAe 0 (5)
  • a In vitro data from multiple experiments are summarized as follows (wild-type E6 activity = 100%): +++, 51 to 100%; ++, 21 to 50%; +, 6 to 20%; +/−, 1 to 5%; −, <1%.

  • b Number of experiments that yielded immortal cells. The number of experiments performed is in parentheses.

  • c Data for p53 binding, degradation, and MEC immortalization are from reference 16.

  • d ND, not determined.

  • e NA, not applicable.